MTNB - Matinas BioPharma Holdings, Inc.

NYSE American - Nasdaq Real Time Price. Currency in USD
0.9451
-0.1149 (-10.84%)
As of 1:18PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close1.0600
Open1.0000
Bid0.0000 x 900
Ask0.0000 x 1000
Day's Range0.8900 - 1.0200
52 Week Range0.3240 - 1.6000
Volume2,563,273
Avg. Volume1,622,075
Market Cap89.441M
Beta (3Y Monthly)1.65
PE Ratio (TTM)N/A
EPS (TTM)-0.1630
Earnings DateAug 6, 2018 - Aug 10, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.00
Trade prices are not sourced from all markets
  • GlobeNewswireyesterday

    Matinas BioPharma Announces Issuance of Key U.S. Patent for Prescription-Only Next Generation Omega-3 MAT9001 Providing Protection Through 2033

    Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, announced today that the U.S. Patent and Trademark Office (“USPTO”) issued U.S. Patent No. 10,058,521 entitled, “Omega-3 pentaenoic acid compositions and methods of use” to the Company. The issued patent provides additional intellectual property protection for MAT9001, Matinas’ proprietary prescription-only omega-3 fatty acid-based composition under development for the treatment of cardiovascular and metabolic conditions, through 2033. The issued patent claims cover the Company’s proprietary methods relating to reducing triglyceride levels, total cholesterol, VLDL-cholesterol or apolipoprotein C-III by administering a pharmaceutical composition comprising omega-3 fatty acids comprising eicosapentaenoic acid (EPA) and docosapentaenoic acid (DPA).

  • GlobeNewswire3 days ago

    Matinas BioPharma to Present at the 8th Annual Partnership Opportunities in Drug Delivery Conference

    Dr. Mannino will give an oral presentation titled, “Enabling the Intracellular Delivery of Life-Changing Medicines,” as part of the conference’s Drug Delivery Technology Presentations Session: Non-Injectable Technologies: Oral, discussing controlled release, modified-release, colon-targeted, and orally-disintegrating delivery systems, as well as bioavailability & solubility enhancing technologies. As part of his presentation, Dr. Mannino will discuss the Company’s differentiated lipid nano-crystal (LNC) platform technology which offers an intracellular drug delivery solution with potential advantages for a range of therapeutics, including demonstrated use with small molecules, nucleic acid polymers, proteins, peptides, and vaccines, as well as the potential for efficient and non-immunogenic delivery of gene editing technologies.

  • GlobeNewswire4 days ago

    Matinas BioPharma Appoints Global Pharmaceutical Drug Development Industry Leader Theresa Matkovits, Ph.D., Chief Development Officer; Further Expands Manufacturing and Clinical Development Team

    - Dr. Matkovits is an industry leader with 20+ years of proven global drug development success bringing 4 approved medicines to several global markets - - Frank Calamusa, CSCP,.

  • GlobeNewswire24 days ago

    Matinas BioPharma to Present at the MicroCap Conference

    BEDMINSTER, N.J., Sept. 25, 2018 -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on enabling targeted intracellular.

  • GlobeNewswirelast month

    Matinas BioPharma Announces Appointment of Industry Leader Patrick G. LePore to Board of Directors

    Matinas BioPharma Holdings, Inc. (NYSE AMER:MTNB), a clinical-stage biopharmaceutical company focused on enabling targeted intracellular delivery of life-changing medicines using its proprietary lipid nano-crystal (LNC) platform technology, today announced the appointment of Patrick G. LePore as Vice Chairman to the Company’s Board of Directors. “We are delighted to welcome Pat to the Matinas Board,” commented Herbert Conrad, Chairman of the Matinas BioPharma Board of Directors.

  • GlobeNewswirelast month

    Matinas BioPharma to Present at the Rodman & Renshaw 20th Annual Global Investment Conference

    As part of his presentation, Mr. Jabbour will provide a corporate update and will discuss the Company’s differentiated LNC drug delivery platform which offers an intracellular drug delivery solution with potential advantages for a range of therapeutics, including small molecules, nucleic acid polymers, proteins, peptides, vaccines, as well as the targeted delivery of gene editing technologies. Additionally, Mr. Jabbour will provide an overview of the Company's lead and platform-validating product candidate, MAT2203, which utilizes its proprietary LNC formulation technology for the safe and effective delivery of the broad-spectrum fungicidal agent, amphotericin B. Based on the positive patient clinical data reported in 2017 and a positive face-to-face interaction with the FDA in 2018, Matinas has designed a streamlined and risk-mitigated development program focused on  a potential pivotal Phase 2 trial of MAT2203 for the prevention of IFIs in patients with acute lymphoblastic leukemia.

  • GlobeNewswire2 months ago

    Matinas BioPharma to Present at the U.S. FDA Development of Non-Traditional Therapies for Bacterial Infections Workshop

    Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on enabling targeted intracellular delivery of life-changing medicines using its proprietary lipid nano-crystal (LNC) platform technology, announced today that Raphael Mannino, Ph.D., Chief Scientific Officer of Matinas will present at the public workshop entitled “Development of Non-Traditional Therapies for Bacterial Infections,” being held by the U.S. Food and Drug Administration (FDA) August 21-22, 2018. The purpose of the public workshop is to discuss the general development considerations of non-traditional therapies, including preclinical development, early clinical studies, and Phase 3 clinical trial designs to evaluate safety and efficacy.

  • GlobeNewswire2 months ago

    Matinas BioPharma Reports Second Quarter 2018 Financial Results and Provides Corporate Update

    –Management intently focused on advancing proprietary and highly differentiated lipid nano-crystal platform delivery technology–. –Multiple discussions with strategic partners remain ongoing–. –­Lead platform-validating ...

  • ACCESSWIRE3 months ago

    Breakfast Technical Briefing on Neptune Technologies & Bioressources and Three Other Additional Biotech Stocks

    LONDON, UK / ACCESSWIRE / July 25, 2018 / If you want a free Stock Review on NEPT sign up now at www.wallstequities.com/registration. Under evaluation this morning are the following equities: Magenta Therapeutics Inc. (MGTA), Matinas BioPharma Holdings Inc. (NYSE AMER: MTNB), MyoKardia Inc. (NASDAQ: MYOK), and Neptune Technologies & Bioressources Inc. (NASDAQ: NEPT).

  • Matinas BioPharma Holdings Inc (NYSEMKT:MTNB): Is Breakeven Near?
    Simply Wall St.4 months ago

    Matinas BioPharma Holdings Inc (NYSEMKT:MTNB): Is Breakeven Near?

    Matinas BioPharma Holdings Inc’s (AMEX:MTNB): Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing antifungal and anti-bacterial therapeutics for the treatment of various infections in theRead More...

  • ACCESSWIRE7 months ago

    Matinas BioPharma Holdings, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 19, 2018 / Matinas BioPharma Holdings, Inc. (NYSE American: MTNB ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 19, 2018, at ...